Catalyst Biosciences (FRA:HGF2) EPS (Basic) : €-1.30 (TTM As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Catalyst Biosciences EPS (Basic)?

Catalyst Biosciences's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was €-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.30.

Catalyst Biosciences's EPS (Diluted) for the three months ended in Sep. 2023 was €-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.30.

Catalyst Biosciences's EPS without NRI for the three months ended in Sep. 2023 was €-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Catalyst Biosciences EPS (Basic) Historical Data

The historical data trend for Catalyst Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences EPS (Basic) Chart

Catalyst Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-2.36

-4.14

-2.41

-2.54

-0.25

Catalyst Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Basic)	Get a 7-Day Free Trial															-0.16	-1.21	0.01	-0.07	-0.04

Catalyst Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Catalyst Biosciences's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.78	-	0)	/	31.546
	=	-0.25

Catalyst Biosciences's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.477	-	0)	/	37.977
	=	-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.30

Catalyst Biosciences (FRA:HGF2) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Catalyst Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (FRA:HGF2) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080

Website

https://www.catalystbiosciences.com

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Catalyst Biosciences Headlines

No Headlines